Condensed Consolidated Interim Financial Statements as of March 31, 2018

Bayer Group
Consolidated Income Statements

 

 

Q1 2017

 

Q1 2018

 

 

€ million

 

€ million

2017 figures restated

1

For definition see Annual Report 2017, Chapter “Alternative Performance Measures Used by the Bayer Group.”

Net sales

 

9,680

 

9,138

Cost of goods sold

 

(2,987)

 

(2,909)

Gross profit

 

6,693

 

6,229

Selling expenses

 

(2,667)

 

(2,509)

Research and development expenses

 

(1,094)

 

(1,040)

General administration expenses

 

(460)

 

(427)

Other operating income

 

159

 

152

Other operating expenses

 

(204)

 

(95)

EBIT1

 

2,427

 

2,310

Equity-method income (loss)

 

(7)

 

71

Financial income

 

32

 

370

Financial expenses

 

(321)

 

(311)

Financial result

 

(296)

 

130

Income before income taxes

 

2,131

 

2,440

Income taxes

 

(424)

 

(494)

Income from continuing operations after income taxes

 

1,707

 

1,946

of which attributable to noncontrolling interest

 

(2)

 

of which attributable to Bayer AG stockholders (net income)

 

1,709

 

1,946

Income from discontinued operations after income taxes

 

564

 

8

of which attributable to noncontrolling interest

 

190

 

of which attributable to Bayer AG stockholders (net income)

 

374

 

8

Income after income taxes

 

2,271

 

1,954

of which attributable to noncontrolling interest

 

188

 

of which attributable to Bayer AG stockholders (net income)

 

2,083

 

1,954

 

 

 

 

 

 

 

 

Earnings per share

 

 

 

 

From continuing operations

 

 

 

 

Basic

 

1.96

 

2.23

Diluted

 

1.96

 

2.23

From discontinued operations

 

 

 

 

Basic

 

0.43

 

0.01

Diluted

 

0.43

 

0.01

From continuing and discontinued operations

 

 

 

 

Basic

 

2.39

 

2.24

Diluted

 

2.39

 

2.24

Compare to Last Year